Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)

Hiroshi Nomoto,Jun Takeuchi,Aika Miya,Shinji Taneda,Tatsuya Atsumi,Kyu Yong Cho,Yoshio Kurihara,Shin Aoki,Hideaki Miyoshi,Hiraku Kameda,Hiroki Yokoyama,Sho Furusawa,Akinobu Nakamura,So Nagai,Ichiro Sakuma

doi:10.1136/bmjopen-2021-056885

Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)

Hiroshi Nomoto, Jun Takeuchi + Show 13 more

Open Access

https://doi.org/10.1136/bmjopen-2021-056885

Copy DOI

Journal: BMJ Open	Publication Date: May 1, 2022
Citations: 3	License type: open-access

Affiliation: Hokkaido University, Hokkaido University Hospital, NTT Medical Center, Hokko Memorial Hospital

#Oral Semaglutide #Dipeptidyl Peptidase-4 Inhibitor + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionIncretin-based therapies exert antihyperglycaemic effects in patients with type 2 diabetes (T2D) in a blood glucose concentration-dependent fashion. The first-in-class oral glucagon-like peptide-1 receptor agonist semaglutide has potent effects on...

Full Text